Gosset Ownership
Private
Employees
~2
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Seurat Therapeutics General Information
Developing an Insulin-like-growth factor-1 (IGF-1) nasal spray formulation that can relieve migraines within 30 minutes by targeting the root cause rather than alleviating symptoms. The therapy mimics the anti-migraine effects of environmental enrichment by reducing brain inflammation and the local concentration of inflammatory cytokines[1][7].
Contact Information
Primary Industry
Biotech
Corporate Office
Chicago, Illinois
United States
United States
Drug Pipeline
Pre-clinical
Key Partnerships
University of Chicago
Seurat Therapeutics Funding
No funding data available
To view Seurat Therapeutics's complete valuation and funding history, request access »